Laurent Meijer

List of Publications by Year in Descending Order

300 papers	22,566 citations	72 h-index	142 g-index
313 ext. papers	24,125 ext. citations	6.1 avg, IF	6.33 L-index

#	Paper	IF	Citations
300	LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. *Oncogenesis*, **2021**, 10, 40	6.6	
299	Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	8
298	Exploring Kinase Inhibition Properties of 9-pyrimido[5,4-]- and [4,5-]indol-4-amine Derivatives. *Pharmaceuticals*, **2020**, 13,	5.2	2
297	Long-Term Fipronil Treatment Induces Hyperactivity in Female Mice. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	6
296	An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
295	A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment. *Scientific Reports*, **2020**, 10, 1143	4.9	6
294	(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. *Scientific Reports*, **2020**, 10, 21700	4.9	5
293	A Collection of Bioactive Nitrogen-Containing Molecules from the Marine Sponge. *Marine Drugs*, **2019**, 17,	6	5
292	Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models. *Scientific Reports*, **2019**, 9, 6653	4.9	7
291	Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice. *Acta Neuropathologica Communications*, **2019**, 7, 46	7.3	19
290	Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation. *Frontiers in Neurology*, **2019**, 10, 124	4.1	12
289	Decrease in p3-Alc37 and p3-Alc40, products of Alcadein generated by secretase cleavages, in aged monkeys and patients with Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 740-750	6	1
288	-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors. *Molecules*, **2019**, 24,	4.8	11
287	Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-]quinazolin-9(8)-one, a Promising Inhibitor of DYRK1A. *Pharmaceuticals*, **2019**, 12,	5.2	6
286	Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a. *Human Molecular Genetics*, **2019**, 28, 1561-1577	5.6	21
285	Induction of Amyloid-42 Production by Fipronil and Other Pyrazole Insecticides. *Journal of Alzheimer's Disease*, **2018**, 62, 1663-1681	4.3	20
284	Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. *Molecules*, **2018**, 23,	4.8	19

283	Genetic and pharmacological inhibition of Cdk1 provides neuroprotection towards ischemic neuronal death. *Cell Death Discovery*, **2018**, 4, 43	6.9	13
282	A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1 inhibitor. *Future Medicinal Chemistry*, **2018**, 10, 2411-2430	4.1	4
281	Development of Kinase Inhibitors via Metal-Catalyzed C?H Arylation of 8-Alkyl-thiazolo[5,4-]-quinazolin-9-ones Designed by Fragment-Growing Studies. *Molecules*, **2018**, 23,	4.8	4
280	Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A. *DMM Disease Models and Mechanisms*, **2018**, 11,	4.1	31
279	Casein kinase 1 and 1 as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8. *American Journal of Physiology - Renal Physiology*, **2018**, 315, F57-F73	4.3	3
278	Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. *PLoS ONE*, **2018**, 13, e0196761	3.7	14
277	Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening. *Molecular Informatics*, **2017**, 36, 1600123	3.8	1
276	N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1 inhibitors: Synthesis, biological evaluation and molecular modeling studies. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 2663-2667	2.9	7
275	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 1183-1199	6.8	34
274	A Simple Isomerization of the Purine Scaffold of a Kinase Inhibitor, Roscovitine, Affords a Four- to Seven-Fold Enhancement of Its Affinity for Four CDKs. Could This Be Traced Back to Conjugation-Induced Stiffenings/Loosenings of Rotational Barriers?. *ACS Omega*, **2017**, 2, 3467-3474	3.9	6
273	Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor. *European Journal of Medicinal Chemistry*, **2017**, 125, 696-709	6.8	22
272	Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases. *Marine Drugs*, **2017**, 15,	6	24
271	Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	6
270	Harnessing Neutrophil Survival Mechanisms during Chronic Infection by : Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 243	5.9	9
269	Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4327-9	2.9	13
268	Chloromethylhalicyclamine B, a Marine-Derived Protein Kinase CK1 Inhibitor. *Journal of Natural Products*, **2016**, 79, 2953-2960	4.9	24
267	Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure. *European Journal of Medicinal Chemistry* , **2016**, 118, 170-7	6.8	24
266	Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. *Human Molecular Genetics*, **2016**, 25, 2245-2253	5.6	33

265	Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1. *Journal of Medicinal Chemistry*, **2016**, 59, 1140-1148	8.3	30
264	Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. *Journal of Innate Immunity*, **2016**, 8, 330-49	6.9	27
263	From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2822-33	5.9	36
262	Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases. *Molecules*, **2016**, 21,	4.8	10
261	Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the H□ershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation. *Molecules*, **2016**, 21,	4.8	4
260	5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of Trypanosoma brucei bloodstream forms. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 3790-800	3.4	15
259	Specific Triazine Herbicides Induce Amyloid-□42 Production. *Journal of Alzheimer□s Disease*, **2016**, 54, 1593-1605	4.3	11
258	Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 115, 311-25	6.8	12
257	Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 124, 920-934	6.8	7
256	Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. *European Journal of Medicinal Chemistry*, **2015**, 101, 274-87	6.8	20
255	10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. *Journal of Medicinal Chemistry*, **2015**, 58, 3131-43	8.3	70
254	A□42 lowering agents from the marine-derived fungus Dichotomomyces cejpii. *Steroids*, **2015**, 104, 182-8	2.8	19
253	TRPC6 channel translocation into phagosomal membrane augments phagosomal function. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E6486-95	11.5	36
252	Dispacamide E and other bioactive bromopyrrole alkaloids from two Indonesian marine sponges of the genus Stylissa. *Natural Product Research*, **2015**, 29, 231-8	2.3	24
251	Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. *Journal of Biomedical Science*, **2015**, 22, 57	13.3	2
250	Novel Adociaquinone Derivatives from the Indonesian Sponge Xestospongia sp. *Marine Drugs*, **2015**, 13, 2617-28	6	18
249	Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors. *European Journal of Medicinal Chemistry*, **2015**, 92, 124-34	6.8	31
248	New 5-ylidene rhodanine derivatives based on the dispacamide A model. *Molecular Diversity*, **2014**, 18, 375-88	3.1	11

247	Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis. *Neuro-Oncology*, **2014**, 16, 1484-98	1	15
246	Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 1501-15	5.9	34
245	Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 83, 617-29	6.8	11
244	Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5037-40	2.9	14
243	9- and 11-Substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma. *European Journal of Medicinal Chemistry*, **2014**, 83, 274-83	6.8	29
242	The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. *Biochemical Pharmacology*, **2014**, 91, 157-67	6	14
241	Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. *Journal of Natural Products*, **2014**, 77, 1117-22	4.9	39
240	Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 80, 352-63	6.8	33
239	Microwave Assisted Organic Synthesis (MAOS) of New Dispacamide A Derivatives Bearing a Thiazolinone Platform, Biological Assays on Inhibition of Protein Kinases and Cell Effects. *Current Microwave Chemistry*, **2014**, 1, 33-40	0.7	1
238	Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents. *Molecules*, **2014**, 19, 15237-57	4.8	13
237	Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors. *Cell Cycle*, **2014**, 13, 984-91	4.7	16
236	Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 1909-15	3.4	10
235	cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease. *Molecular Pharmacology*, **2014**, 85, 441-50	4.3	23
234	Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I. *Molecules*, **2014**, 19, 15546-71	4.8	35
233	Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines. *European Journal of Medicinal Chemistry*, **2013**, 62, 728-37	6.8	15
232	Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6784-8	2.9	15
231	CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 19525-30	11.5	58
230	Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice. *BMC Pharmacology & Toxicology*, **2013**, 14, 50	2.6	7

229	Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition. *Journal of Medicinal Chemistry*, **2013**, 56, 7289-301	8.3	39
228	Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. *European Journal of Medicinal Chemistry*, **2013**, 59, 283-95	6.8	34
227	3,6-Diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-5-carbonitriles are selective inhibitors of Plasmodium falciparum glycogen synthase kinase-3. *Journal of Medicinal Chemistry*, **2013**, 56, 264-75	8.3	45
226	A western blot assay to measure cyclin dependent kinase activity in cells or in vitro without the use of radioisotopes. *FEBS Letters*, **2013**, 587, 3089-95	3.8	26
225	Targeting cyclin-dependent kinases in anti-neoplastic therapy. *Current Opinion in Cell Biology*, **2013**, 25, 772-9	9	67
224	Synthesis and evaluation of new potent inhibitors of CK1 and CDK5, two kinases involved in Alzheimer disease. *Medicinal Chemistry Research*, **2013**, 22, 3247-3258	2.2	7
223	Cyclin-dependent kinase inhibitors closer to market launch?. *Expert Opinion on Therapeutic Patents*, **2013**, 23, 945-63	6.8	25
222	Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 125-31	2.9	28
221	Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 22-26	4.3	57
220	Inhibition of NF-B-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells. *Clinical Cancer Research*, **2013**, 19, 2393-405	12.9	28
219	Indirubin derivative 6BIO suppresses metastasis. *Cancer Research*, **2013**, 73, 6004-12	10.1	33
218	Aftins increase amyloid-42, lower amyloid-38, and do not alter amyloid-40 extracellular production in vitro: toward a chemical model of Alzheimer's disease?. *Journal of Alzheimer's Disease* , **2013**, 35, 107-20	4.3	13
217	Natural aristolactams and aporphine alkaloids as inhibitors of CDK1/cyclin B and DYRK1A. *Molecules*, **2013**, 18, 3018-27	4.8	17
216	Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. *European Journal of Medicinal Chemistry*, **2012**, 49, 379-96	6.8	69
215	Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. *European Journal of Medicinal Chemistry*, **2012**, 58, 171-83	6.8	40
214	Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K inhibitors. *European Journal of Medicinal Chemistry*, **2012**, 57, 225-33	6.8	21
213	An efficient approach to dispacamide A and its derivatives. *Organic and Biomolecular Chemistry*, **2012**, 10, 978-87	3.9	19
212	CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. *Cell Cycle*, **2012**, 11, 4040-6	4.7	43

211	Use of ATP analogs to inhibit HIV-1 transcription. *Virology*, **2012**, 432, 219-31	3.6	19
210	Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors. *Molecular Diversity*, **2012**, 16, 659-67	3.1	12
209	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. *Journal of Medicinal Chemistry*, **2012**, 55, 9312-30	8.3	146
208	Small-molecule inducers of A□42 peptide production share a common mechanism of action. *FASEB Journal*, **2012**, 26, 5115-23	0.9	15
207	Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts. *Journal of Medicinal Chemistry*, **2012**, 55, 9589-606	8.3	42
206	Synthesis, biological evaluation, and molecular modeling of natural and unnatural flavonoidal alkaloids, inhibitors of kinases. *Journal of Medicinal Chemistry*, **2012**, 55, 2811-9	8.3	29
205	Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide. *European Journal of Medicinal Chemistry*, **2012**, 54, 626-36	6.8	20
204	Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors. *European Journal of Medicinal Chemistry*, **2012**, 56, 210-6	6.8	7
203	Synthesis of N,N'-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases. *European Journal of Medicinal Chemistry*, **2012**, 58, 581-90	6.8	9
202	Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents. *European Journal of Medicinal Chemistry*, **2012**, 58, 543-56	6.8	50
201	Phenanthrene derivatives from Appendicula reflexa as new CDK1/cyclin B inhibitors. *Phytochemistry Letters*, **2012**, 5, 814-818	1.9	14
200	Synthesis of New N,N'-Bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)piperazine Derivatives Under Microwave Irradiation and Preliminary Biological Evaluation. *Scientia Pharmaceutica*, **2012**, 80, 825-36	4.3	11
199	Targeting low molecular weight cyclin E (LMW-E) in breast cancer. *Breast Cancer Research and Treatment*, **2012**, 132, 575-88	4.4	30
198	Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents. *Biochemical Journal*, **2012**, 446, 373-81	3.8	34
197	Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts. *Planta Medica*, **2012**, 78, 951-6	3.1	27
196	Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. *Journal of Medicinal Chemistry*, **2011**, 54, 4474-89	8.3	82
195	A practical approach to new (5Z) 2-alkylthio-5-arylmethylene-1-methyl-1,5-dihydro-4H-imidazol-4-one derivatives. *Molecules*, **2011**, 16, 7377-90	4.8	5
194	Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. *Journal of Medicinal Chemistry*, **2011**, 54, 4172-86	8.3	107

193	Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. *Virology*, **2011**, 415, 56-68	3.6	22
192	Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents. *European Journal of Medicinal Chemistry*, **2011**, 46, 5416-34	6.8	39
191	A one-pot synthesis and biological activity of ageladine A and analogues. *Journal of Medicinal Chemistry*, **2011**, 54, 2492-503	8.3	26
190	An expeditious, environment-friendly, and microwave-assisted synthesis of 5-isatinylidenerhodanine derivatives. *Chemical Papers*, **2011**, 65,	1.9	5
189	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 359-73	3.4	16
188	Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. *Cancer Research*, **2011**, 71, 3377-86	10.1	41
187	Plasmodium falciparum NIMA-related kinase Pfnek-1: sex specificity and assessment of essentiality for the erythrocytic asexual cycle. *Microbiology (United Kingdom)*, **2011**, 157, 2785-2794	2.9	30
186	Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. *PLoS ONE*, **2010**, 5, e12117	3.7	72
185	CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. *Genes and Cancer*, **2010**, 1, 369-80	2.9	57
184	Cyclin-dependent kinase inhibitors: a survey of recent patent literature. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 377-404	6.8	50
183	Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd(0) catalysed reductive N-heteroannulation. *Organic and Biomolecular Chemistry*, **2010**, 8, 4625-36	3.9	16
182	Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis. *Neurotoxicology and Teratology*, **2010**, 32, 212-9	3.9	13
181	Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4940-4	2.9	22
180	Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. *European Journal of Medicinal Chemistry*, **2010**, 45, 805-10	6.8	29
179	Development of 5-benzylpaullones and paullone-9-carboxylic acid alkyl esters as selective inhibitors of mitochondrial malate dehydrogenase (mMDH). *European Journal of Medicinal Chemistry*, **2010**, 45, 335-42	6.8	25
178	microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection. *Journal of Rnai and Gene Silencing*, **2010**, 6, 386-400		13
177	An Efficient Method for the Preparation of New Analogs of Leucettamine B under Solvent-Free Microwave Irradiation. *Heterocycles*, **2009**, 78, 1191	0.8	11
176	6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. *International Journal for Parasitology*, **2009**, 39, 1289-303	4.3	61

175	Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1-5, GSK-3) inhibitors. *European Journal of Medicinal Chemistry* , **2009**, 44, 708-16	6.8	17
174	Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 4420-4	3.4	64
173	Identification of potential cellular targets of aloisine A by affinity chromatography. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5572-82	3.4	5
172	Synthesis and kinase inhibitory activity of novel substituted indigoids. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6257-63	3.4	49
171	Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4566-9	2.9	67
170	Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue. *Journal of Medicinal Chemistry*, **2009**, 52, 655-63	8.3	56
169	Practical Synthesis of Roscovitine and CR8. *Organic Process Research and Development*, **2009**, 13, 641-644	3.9	17
168	7-Bromoindirubin-3'-oxime uncovers a serine protease-mediated paradigm of necrotic cell death. *Biochemical Pharmacology*, **2008**, 76, 39-52	6	20
167	9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. *Journal of Medicinal Chemistry*, **2008**, 51, 2196-207	8.3	76
166	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. *Journal of Medicinal Chemistry*, **2008**, 51, 737-51	8.3	119
165	Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. *Journal of Medicinal Chemistry*, **2008**, 51, 6421-31	8.3	98
164	Butyrolactone I derivatives from Aspergillus terreus carrying an unusual sulfate moiety. *Journal of Natural Products*, **2008**, 71, 689-92	4.9	35
163	Photoreactivity of indirubin derivatives. *Photochemical and Photobiological Sciences*, **2008**, 7, 328-36	4.2	5
162	Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. *Molecular Pharmacology*, **2008**, 74, 1620-9	4.3	15
161	Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. *Cancer Research*, **2008**, 68, 7966-74	10.1	88
160	N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. *Molecular Cancer Therapeutics*, **2008**, 7, 2713-24	6.1	45
159	Anticancer alkaloid lamellarins inhibit protein kinases. *Marine Drugs*, **2008**, 6, 514-27	6	104
158	Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. *European Journal of Medicinal Chemistry*, **2008**, 43, 1469-77	6.8	50

157	Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 4932-53	3.4	51
156	Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. *Journal of Medicinal Chemistry*, **2008**, 51, 5229-42	8.3	108
155	Synthesis of 6-Pyridylaminopurines. *Heterocycles*, **2008**, 75, 1735	0.8	3
154	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. *Journal of Medicinal Chemistry*, **2007**, 50, 4027-37	8.3	55
153	A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo. *Journal of Physiological Sciences*, **2007**, 57, 235-9	2.3	21
152	Access to Paullone Analogues by Intramolecular Heck Reaction. *Helvetica Chimica Acta*, **2007**, 90, 753-763		26
151	Towards the syntheses of N-H and N-alkylated derivatives of meridianins. *Journal of Heterocyclic Chemistry*, **2007**, 44, 793-801	1.9	26
150	Inverse in silico screening for identification of kinase inhibitor targets. *Chemistry and Biology*, **2007**, 14, 1207-14		71
149	A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 130-41	3.4	16
148	Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. *Biotechnology Journal*, **2007**, 2, 68-75	5.6	47
147	Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. *Cancer Research*, **2007**, 67, 8325-34	10.1	84
146	Purification of CK1 by affinity chromatography on immobilised axin. *Protein Expression and Purification*, **2007**, 54, 101-9	2	57
145	Antimalarial drug discovery: targeting protein kinases. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 279-90	6.4	65
144	Diversity of the intracellular mechanisms underlying the anti-tumor properties of indirubins. *International Congress Series*, **2007**, 1304, 60-74		8
143	Modular asymmetric synthesis of aigialomycin D, a kinase-inhibitory scaffold. *Angewandte Chemie - International Edition*, **2006**, 45, 3951-4	16.4	72
142	Modular Asymmetric Synthesis of Aigialomycin D, a Kinase-Inhibitory Scaffold. *Angewandte Chemie*, **2006**, 118, 4055-4058	3.6	13
141	Replication-dependent DNA damage response triggered by roscovitine induces an uncoupling of DNA replication proteins. *Cell Cycle*, **2006**, 5, 2153-9	4.7	12
140	Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. *Cancer Research*, **2006**, 66, 10720-8	10.1	75

139	Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. *Journal of Medicinal Chemistry*, **2006**, 49, 789-99	8.3	84
138	(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. *Experimental Cell Research*, **2006**, 312, 2394-400	4.2	39
137	3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents. *Journal of Medicinal Chemistry*, **2006**, 49, 4638-49	8.3	64
136	Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. *European Journal of Medicinal Chemistry*, **2006**, 41, 296-305	6.8	85
135	Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 6434-43	3.4	78
134	Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3144-6	2.9	10
133	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 3419-23	2.9	51
132	Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3758-65	3.4	213
131	Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 4477-82	3.4	61
130	Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors. *Enzyme Inhibitors Series*, **2006**, 227-249		2
129	Evaluation of CDK Inhibitor Selectivity. *Enzyme Inhibitors Series*, **2006**, 103-119		5
128	(R)-Roscovitine (CYC202, Seliciclib). *Enzyme Inhibitors Series*, **2006**, 187-225		9
127	CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases. *Drug News and Perspectives*, **2006**, 19, 325-8		21
126	Mechanism of CDK5/p25 binding by CDK inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 671-9	8.3	152
125	Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. *Journal of Medicinal Chemistry*, **2005**, 48, 737-43	8.3	101
124	Synthesis of acridinyl-thiazolino derivatives and their evaluation for anti-inflammatory, analgesic and kinase inhibition activities. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 4291-9	3.4	81
123	Epoxide-containing side chains enhance antiproliferative activity of paullones. *European Journal of Medicinal Chemistry*, **2005**, 40, 655-61	6.8	33
122	Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases. *Journal of Medicinal Chemistry*, **2005**, 48, 6843-54	8.3	57

121	Degradation of Hof1 by SCF(Grr1) is important for actomyosin contraction during cytokinesis in yeast. *EMBO Journal*, **2005**, 24, 1440-52	13	98
120	Characterization of two T. gondii CK1 isoforms. *Molecular and Biochemical Parasitology*, **2005**, 141, 15-27	1.9	30
119	Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. *Chemistry and Biodiversity*, **2005**, 2, 51-65	2.5	36
118	Structure-aided optimization of kinase inhibitors derived from alsterpaullone. *ChemBioChem*, **2005**, 6, 541-9	3.8	35
117	Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 823-5	2.9	41
116	Synthesis and evaluation of the antiproliferative activity of novel thiazoloquinazolinone kinases inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2005**, 20, 557-68	5.6	27
115	Roscovitine targets, protein kinases and pyridoxal kinase. *Journal of Biological Chemistry*, **2005**, 280, 31208-19	5.4	278
114	Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. *Journal of Biological Chemistry*, **2005**, 280, 31220-9	5.4	62
113	Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase. *Journal of Zhejiang University Science B*, **2005**, 6, 656-63		7
112	Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 3033-42	5.9	86
111	CDK1/cyclin B regulation during oocyte maturation in two closely related lugworm species, Arenicola marina and Arenicola defodiens. *Development Growth and Differentiation*, **2004**, 46, 71-82	3	9
110	Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. *Nature Medicine*, **2004**, 10, 55-63	50.5	1723
109	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. *Oncogene*, **2004**, 23, 4400-12	9.2	81
108	Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. *Oncogene*, **2004**, 23, 8206-15	9.2	65
107	Antiinflammatory, analgesic and kinase inhibition activities of some acridine derivatives. *Open Chemistry*, **2004**, 2, 1-15	1.6	25
106	1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 413-6	2.9	154
105	CDK1-inhibitory activity of paullones depends on electronic properties of 9-substituents. *Archiv Der Pharmazie*, **2004**, 337, 486-92	4.3	28
104	Synthesis and target identification of hymenialdisine analogs. *Chemistry and Biology*, **2004**, 11, 247-59		115

103	Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2004**, 1697, 181-96	4	83
102	Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 1703-7	2.9	166
101	Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2004**, 19, 585-93	5.6	6
100	Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis. *Journal of Medicinal Chemistry*, **2004**, 47, 3236-41	8.3	67
99	Polyprenyl-hydroquinones and -furans from three marine sponges inhibit the cell cycle regulating phosphatase CDC25A. *Natural Product Research*, **2004**, 18, 1-9	2.3	21
98	Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. *Journal of Medicinal Chemistry*, **2004**, 47, 22-36	8.3	89
97	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. *Journal of Medicinal Chemistry*, **2004**, 47, 935-46	8.3	308
96	Expression and activity of cyclin-dependent kinases and glycogen synthase kinase-3 during NT2 neuronal differentiation. *NeuroSignals*, **2004**, 13, 134-43	1.9	7
95	Pharmacological inhibitors of glycogen synthase kinase 3. *Trends in Pharmacological Sciences*, **2004**, 25, 471-80	13.2	510
94	Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. *Journal of Medicinal Chemistry*, **2003**, 46, 222-36	8.3	129
93	GSK-3-selective inhibitors derived from Tyrian purple indirubins. *Chemistry and Biology*, **2003**, 10, 1255-66		632
92	Isolation of drugs active against mammalian prions using a yeast-based screening assay. *Nature Biotechnology*, **2003**, 21, 1075-81	44.5	154
91	Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties. *Journal of Medicinal Chemistry*, **2003**, 46, 876-9	8.3	27
90	Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. *Accounts of Chemical Research*, **2003**, 36, 417-25	24.3	309
89	The inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti. *FASEB Journal*, **2003**, 17, 2136-8	0.9	17
88	Molecular cloning and characterisation of p15(CDK-BP), a novel CDK-binding protein. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2002**, 1589, 219-31	4.9	4
87	Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. *Biochemical Pharmacology*, **2002**, 64, 819-25	6	35
86	Protein kinases as drug targets in parasitic protozoa. *Trends in Parasitology*, **2002**, 18, 366-71	6.4	64

85	Synthesis of paullones with aminoalkyl side chains. *Archiv Der Pharmazie*, **2002**, 335, 311-7	4.3	22
84	Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. *ChemBioChem*, **2002**, 3, 897-901	3.8	53
83	p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. *Oncogene*, **2002**, 21, 6413-24	9.2	57
82	Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 2177-84	3.4	41
81	Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. *Molecular Biology of the Cell*, **2002**, 13, 4013-28	3.5	212
80	Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor. *Journal of Biological Chemistry*, **2002**, 277, 25493-501	5.4	118
79	Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. *Journal of Virology*, **2002**, 76, 7874-82	6.6	100
78	Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. *Journal of Medicinal Chemistry*, **2002**, 45, 1741-7	8.3	87
77	Pharmacological inhibitors of cyclin-dependent kinases. *Trends in Pharmacological Sciences*, **2002**, 23, 417-25	13.2	478
76	CDK Inhibitors **2002**, 145-167		2
75	Pfnek-1, a NIMA-related kinase from the human malaria parasite Plasmodium falciparum Biochemical properties and possible involvement in MAPK regulation. *FEBS Journal*, **2001**, 268, 2600-8		89
74	Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 3049-54	3.4	38
73	Synthesis of a new series of purine derivatives and their anti-cyclin-dependent kinase activities. *Journal of Heterocyclic Chemistry*, **2001**, 38, 299-303	1.9	13
72	In vitro activity of antimitotic compounds against the microsporidium Encephalitozoon intestinalis. *Journal of Eukaryotic Microbiology*, **2001**, Suppl, 99S-100S	3.6	3
71	Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. *Oncogene*, **2001**, 20, 3786-97	9.2	123
70	Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. *Biochemical Pharmacology*, **2001**, 62, 341-8	6	53
69	Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. *Structure*, **2001**, 9, 389-97	5.2	122
68	Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. *FASEB Journal*, **2001**, 15, 2288-90	0.9	25

67	In vitro activities of two antimitotic compounds, pancratistatin and 7-deoxynarciclasine, against Encephalitozoon intestinalis, a microsporidium causing infections in humans. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 3409-15	5.9	27
66	Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. *Journal of Virology*, **2001**, 75, 7266-79	6.6	121
65	Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. *Journal of Biological Chemistry*, **2001**, 276, 251-60	5.4	546
64	High developmental competence of cattle oocytes maintained at the germinal vesicle stage for 24 hours in culture by specific inhibition of MPF kinase activity. *Molecular Reproduction and Development*, **2000**, 55, 89-95	2.6	166
63	Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. *FEBS Journal*, **2000**, 267, 5983-94		290
62	2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 567-9	2.9	67
61	Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 1819-22	2.9	32
60	Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. *Journal of Biological Chemistry*, **2000**, 275, 390-7	5.4	382
59	Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. *Journal of Biological Chemistry*, **2000**, 275, 8952-8	5.4	78
58	Cyclin E-cdk2 phosphorylation promotes late G1-phase degradation of MyoD in muscle cells. *Experimental Cell Research*, **2000**, 259, 300-7	4.2	53
57	Purification of GSK-3 by affinity chromatography on immobilized axin. *Protein Expression and Purification*, **2000**, 20, 394-404	2	83
56	Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. *Journal of Medicinal Chemistry*, **2000**, 43, 1282-92	8.3	83
55	Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents. *Drug Resistance Updates*, **2000**, 3, 83-88	23.2	45
54	Intra-M phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition. *Journal of Biological Chemistry*, **1999**, 274, 11977-86	5.4	52
53	Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. *Chemistry and Biology*, **1999**, 6, 361-75		217
52	Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1281-93	3.4	53
51	In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor. *Annals of the New York Academy of Sciences*, **1999**, 886, 180-2	6.5	2
50	Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. *Nature*, **1999**, 402, 669-71	50.4	483

49	Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. *Nature Cell Biology*, **1999**, 1, 60-7	23.4	670
48	Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases **1999**, 82, 279-84		72
47	KID, a Kinase Inhibitor Database project **1999**, 82, 165-8		4
46	Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target **1999**, 82, 285-92		94
45	Characterization of a novel cdk1-related kinase. *FEBS Journal*, **1999**, 264, 55-66		4
44	Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. *Journal of Medicinal Chemistry*, **1999**, 42, 2909-19	8.3	275
43	Regulation of M-phase promoting factor (MPF) in Nereis virens oocytes during meiotic maturation. *Invertebrate Reproduction and Development*, **1999**, 36, 175-181	0.7	2
42	ATP-site Directed Inhibitors of Cyclin-dependent Kinases. *Current Medicinal Chemistry*, **1999**, 6, 859-875	4.3	165
41	Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 793-8	2.9	45
40	Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. *Science*, **1998**, 281, 533-8	33.3	631
39	The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. *Experimental Cell Research*, **1998**, 245, 8-18	4.2	128
38	Chemical inhibitors of cyclin-dependent kinases. *Methods in Enzymology*, **1997**, 283, 113-28	1.7	96
37	The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. *Experimental Cell Research*, **1997**, 236, 4-15	4.2	92
36	Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. *FEBS Journal*, **1997**, 243, 518-26		519
35	Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. *FEBS Journal*, **1997**, 243, 527-36		1068
34	The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker. *Cellular and Molecular Neurobiology*, **1997**, 17, 495-507	4.6	14
33	Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. *Journal of Medicinal Chemistry*, **1997**, 40, 408-12	8.3	207
32	Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension. *Plant Journal*, **1997**, 12, 191-202	6.9	90

31	Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. *Journal of Biological Chemistry*, **1996**, 271, 27847-54	5.4	109
30	Chemical inhibitors of cyclin-dependent kinases. *Trends in Cell Biology*, **1996**, 6, 393-7	18.3	190
29	Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. *Proteins: Structure, Function and Bioinformatics*, **1995**, 22, 378-91	4.2	237
28	Chemical inhibitors of cyclin-dependent kinases. *Progress in Cell Cycle Research*, **1995**, 1, 351-63		45
27	Inhibition of cyclin-dependent kinases by purine analogues. *FEBS Journal*, **1994**, 224, 771-86		504
26	Starfish oocyte maturation: from prophase to metaphase. *Seminars in Developmental Biology*, **1994**, 5, 165-171		13
25	Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. *FEBS Letters*, **1994**, 353, 207-11	3.8	114
24	8-Dimethylamino-1-methyladenine, a novel potent antagonist of the 1-methyladenine receptor in starfish oocytes. *FEBS Journal*, **1993**, 213, 155-65		10
23	Interaction between the cell-cycle-control proteins p34cdc2 and p9CKShs2. Evidence for two cooperative binding domains in p9CKShs2. *FEBS Journal*, **1992**, 203, 353-60		31
22	High-mobility-group proteins P1, I and Y as substrates of the M-phase-specific p34cdc2/cyclincdc13 kinase. *FEBS Journal*, **1991**, 196, 557-67		44
21	Starfish Oocytes and Sea Urchin Eggs as Models to Study the Intracellular Mechanisms Controlling the Cell Division Cycle **1990**, 243-255		
20	Starfish oocyte maturation: evidence for a cyclic AMP-dependent inhibitory pathway. *Developmental Biology*, **1989**, 133, 58-66	3.1	45
19	M-phase-specific protein kinase from mitotic sea urchin eggs: cyclic activation depends on protein synthesis and phosphorylation but does not require DNA or RNA synthesis. *Experimental Cell Research*, **1989**, 183, 361-75	4.2	30
18	Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. *Experimental Cell Research*, **1988**, 174, 116-29	4.2	102
17	cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. *Cell*, **1988**, 55, 371-8	56.2	502
16	Starfish oocyte maturation: 1-methyladenine triggers a drop of cAMP concentration related to the hormone-dependent period. *Developmental Biology*, **1987**, 121, 306-15	3.1	58
15	Characterization of maturation-activated histone H1 and ribosomal S6 kinases in sea star oocytes. *Biochemistry*, **1987**, 26, 7960-8	3.2	67
14	Differential regulation of histone H1 and ribosomal S6 kinases during sea star oocyte maturation. *Biochemistry*, **1987**, 26, 7968-74	3.2	37

13	Contrasting effects of fatty acids on oocyte maturation in several starfish species. *Prostaglandins, Leukotrienes, and Medicine*, **1986**, 23, 179-84		18
12	Protein phosphorylation and oocyte maturation. I. Induction of starfish oocyte maturation by intracellular microinjection of a phosphatase inhibitor, alpha-naphthylphosphate. *Experimental Cell Research*, **1986**, 163, 477-88	4.2	36
11	Protein phosphorylation and oocyte maturation. II. Inhibition of starfish oocyte maturation by intracellular microinjection of protein phosphatases 1 and 2A and alkaline phosphatase. *Experimental Cell Research*, **1986**, 163, 489-99	4.2	35
10	Arachidonic acid metabolism in starfish oocytes. *Developmental Biology*, **1986**, 114, 22-33	3.1	27
9	The Role of Calmodulin in Oocyte Maturation **1985**, 129-145		
8	Maturation and fertilization in starfish oocytes. *International Review of Cytology*, **1984**, 86, 129-96		120
7	Calmodulin in starfish oocytes. II. Trypsin treatment suppresses the trifluoperazine-sensitive step. *Developmental Biology*, **1984**, 101, 257-62	3.1	6
6	Arachidonic acid, 12- and 15-hydroxyeicosatetraenoic acids, eicosapentaenoic acid, and phospholipase A2 induce starfish oocyte maturation. *Developmental Biology*, **1984**, 106, 368-78	3.1	47
5	Immobilized methylglyoxal-bis(guanylhydrazone) induces starfish oocyte maturation. *Developmental Biology*, **1983**, 100, 308-17	3.1	15
4	Trifluoperazine-Sensitive Step during Sea Urchin, Echiuroid and Pelecypod Egg Activation. *Development Growth and Differentiation*, **1983**, 25, 469-475	3	9
3	Stimulation of protein phosphorylation during fertilization-induced maturation of Urechis caupo oocytes. *Developmental Biology*, **1982**, 94, 62-70	3.1	33
2	Activation of calmodulin-dependent NAD+ kinase by trypsin. *BBA - Proteins and Proteomics*, **1982**, 702, 143-6		25
1	Calmodulin in starfish oocytes. I. Calmodulin antagonists inhibit meiosis reinitiation. *Developmental Biology*, **1981**, 88, 318-24	3.1	33